Editorial

REFERENCES

• F. Giles, J. Cortes, and H. Kantarjian, Targeting the kinase activity of the BCR-ABL fusion protein in patients with chronic myeloid leukemia, Curr. Mol. Med., 5: 615–623, 2005. [CSA]
   PubMed Web of Science ®Google Scholar
• L. Emens, Trastuzumab, targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer, Am. J. Ther., 12: 243–253, 2005. [CSA]
   PubMedGoogle Scholar
• W. Coley, The treatment of malignant tumors by repeated inoculations of Erysipelas: With a report of ten original cases, Am. J. Med. Sci., 105: 487–511, 1893. [CSA]
   Google Scholar
• A.Y. Huang, P. Golumbek, M. Ahmadzadeh, E. Jaffee, D. Pardoll, and H. Levitsky, Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens, Science, 264: 961–965, 1994. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• A.Y. Huang, P.H. Gulden, A.S. Woods, M.C. Thomas, C.D. Tong, W. Wang, V.H. Engelhard, G. Pasternack, R. Cotter, D. Hunt, D.M. Pardoll, and E.M. Jaffee, The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product, Proc. Natl. Acad. Sci. U.S.A., 93: 9730–9735, 1996. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• R.T. Reilly, L.A. Emens, and E.M. Jaffee, Humoral and cellular immune responses: Independent forces or collaborators in the fight against cancer? Curr. Opin. Invest. Drugs., 2: 133–135, 2001. [CSA]
   PubMedGoogle Scholar
• R.T. Reilly, J.P. Machiels, L.A. Emens, A.M. Ercolini, F.I. Okoye, R.Y. Lei, D. Weintraub, and E.M. Jaffee, The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors, Cancer Res., 61: 880–883, 2001. [CSA]
   PubMed Web of Science ®Google Scholar
• J.M. Kirkwood, J.A. Sosman, V.K. Sondak, S.S. Agarwala, M.S. Ernstoff, and U. Rao, High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: Results of Intergroup Trial E1694/S9512/C509801, J. Clin. Onco., 19: 2370–2380, 2001. [CSA]
   PubMed Web of Science ®Google Scholar
• R. Salgia, T. Lynch, A. Skarin, J. Lucca, C. Lynch, K. Jung, F.S. Hodi, M. Jaklitsch, S. Mentzer, S. Swanson, J. Lukanich, R. Bueno, J. Wain, D. Mathisen, C. Wright, P. Fidias, D. Donahue, S. Clift, S. Hardy, D. Neuberg, R. Mulligan, I. Webb, D. Sugarbaker, M. Mihm, and G. Dranoff, Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma, J. Clin. Oncol., 21: 624–630, 2003. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• U. Keilholz, P. Martus, and C. Scheibenbogen, Immune monitoring of T-cell responses in cancer vaccine development, Clin. Cancer Res., 12: 2346s–2352s, 2006. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• C. Lurquin, B. Lethe, E. De Plaen, V. Corbiere, I. Theate, N. van Baren, P. Coulie, and T. Boon. Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen, J. Exp. Med., 201: 249–257, 2005. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• K. Beck, J. Blansfield, K. Tran, A. Feldman, M. Hughes, R. Royal, U. Kammula, S. Topalian, R. Sherry, D. Kleiner, M. Quezado, I. Lowy, M. Yellin, S. Rosenberg, and J. Yang, Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4, J. Clin. Onco., 24: 2283–2289, 2006. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• A. Ribas, L. Camacho, G. Lopez-Berestein, D. Pavlov, C. Bulanhagul, R. Millham, B. Comin-Anduix, J. Reuben, E. Seja, C. Parker, A. Sharma, J. Glaspy, and J. Gomez-Navarro, Antitumor activity in melanoma and anti-self responses in a phase I trial with anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206, J. Clin. Oncol., 23: 8968–8977, 2005. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• K. Sanderson, R. Scotland, P. Lee, D. Liu, S. Groshen, J. Snively, S. Sian, G. Nichol, T. Davis, T. Keler, M. Yellin, and J. Weber, Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte-antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma, J. Clin. Oncol., 23: 741–750, 2005. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• H. Khong and N. Restifo, Natural selection of tumor variants in the generation of “tumor escape” phenotypes, Nat. Immunol., 3: 999–1005, 2002. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• G. Yamshchikov, D. Mullins, C. Chang, T. Ogino, L. Thompson, J. Presley, H. GAlavotti, W. Aquila, D. Deacon, W. Ross, J. Patterson, V. Engelhard, S. Ferrone, and C. J. Slingluff, Sequential immune escape and shifting of T cell responses in a long-term survivor of melanoma, J. Immunol., 174: 6863–6871, 2005. [CSA]
   PubMed Web of Science ®Google Scholar
• K. Knutson, H. Lu, B. Stone, J. Reiman, M. Behrens, C. Prosperi, E. Gad, A. Smorlesi, and M. Disis, Immunoediting of cancer may lead to epithelial to mesenchymal transition, J. Immunol., 177: 1526–1533, 2006. [CSA]
   PubMed Web of Science ®Google Scholar